Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2023-03-15 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - PXS 6 pages 28.2KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and mentions compliance with ASX Listing Rules. The document is an announcement about new securities being quoted rather than a financial report or detailed financial statement. It does not contain financial results, management discussion, or audit information. Therefore, it fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2023-03-15 English
PXS Securities Trading Policy - Updated 10 Feb 2023 9 pages 232.7KB
Governance Information Classification · 95% confidence The document is titled 'Securities Trading Policy' for Pharmaxis Ltd and discusses rules and regulations regarding insider trading, trading blackout periods, and compliance with securities laws. It focuses on internal policies for directors, officers, and employees about trading company securities and does not contain financial data, earnings, or report content. It is a governance-related document outlining internal rules and compliance practices rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR). The document length is substantial and contains detailed policy information, not a brief announcement or certification, so it is not RNS or RPA.
2023-02-12 English
Change in substantial holding 3 pages 637.6KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, specifically a Notice of change of interests of a substantial holder. It details changes in voting power and relevant interests of Regal Funds Management Pty Limited and its associates in Pharmaxis Ltd. The content includes dates of acquisition, number of securities, and changes in association. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document length is 7484 characters, which is sufficient to contain detailed information rather than just an announcement. There is no indication that this is an annual report, audit report, or any other type of financial or management report. Therefore, the correct classification is MRQ with high confidence.
2023-02-12 English
Half Yearly Report and Accounts 24 pages 738.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Pharmaxis Ltd ASX Half year report – 31 December 2022' and references the half-year ended 31 December 2022, with comparative data for the previous half-year period. It includes detailed financial statements such as consolidated income statement, balance sheet, cash flows, notes to financial statements, directors' report, and auditor's review report. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year. It is explicitly described as a half-year report and is lodged under ASX Listing Rule 4.2A, which pertains to interim financial reports. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-02-09 English
Investor Presentation 28 pages 2.7MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation | February 2023' and contains detailed information about the company's clinical programs, pipeline, financial position, shareholder information, and clinical trial updates. It includes forward-looking statements, executive summary, program updates, and clinical trial designs and interim data. The content is typical of an investor presentation aimed at providing investors with an overview of the company's strategy, financials, and clinical progress. There is no indication that this is a formal regulatory filing like an annual or interim report, audit report, or earnings release. The document is not a transcript of a call, nor is it a voting result or a legal proceeding update. It is a detailed presentation for investors focusing on financials, strategy, and market position, which matches the definition of an Investor Presentation (IP). The document length is substantial (15,000 characters), supporting that it is a full presentation rather than a brief announcement or notice.
2023-02-05 English
Quarterly Activities/Appendix 4C Cash Flow Report 5 pages 226.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements including operating, investing, and financing activities for Pharmaxis Ltd for the quarter ended 31 December 2022. It includes actual financial data such as receipts, payments, cash equivalents, and financing facilities. The document is over 10,000 characters, indicating it is a substantive report rather than a brief announcement. The presence of detailed financial statements and compliance statements aligns with the characteristics of an Interim / Quarterly Report. Therefore, the document is best classified as an Interim / Quarterly Report (IR). Q4 2022
2023-01-30 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.